MicroVue™ FGF-23 ELISA (C-Term)

The MicroVue Human FGF-23 (C-Term) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.


Product Specifications

Citations 35
Specimen

Plasma or Cell Culture Supernatent, 200 µL

LLOQ 1.5 RU/mL
ULOQ N/A
Assay Time 3.5 hours
Cross Reactivity

None

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.
Catalog Number 60-6100
Catalog Number (CE)  
Size 96 wells/test
Price (USD) $725.00
Price (EURO) 640,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

The MicroVue Human FGF-23 (C-Term) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.

Size 96 wells/test
Form

96 well plate with 12 eight-well strips in a resealable foil pouch

Specimen Plasma or Cell Culture Supernatent, 200 µL
Limit of Detection (LOD) 1.5 RU/mL
Lower Limit of Quantitation (LLOQ) 1.5 RU/mL
Upper Limit of Quantitation (ULOQ) N/A
Intra Assay 1.4 - 2.4%
Inter Assay 2.4 - 4.7%
Standards 6
Controls 2
Sample Values

N/A

Assay Time 3.5 hours
Cross Reactivity

None

Storage

Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components

Background

Fibroblast growth factor 23 (FGF-23), which is produced by bone cells, is a novel member of a large family of related proteins. Its gene encodes a 251 amino acid protein. The amino-terminal portion of FGF-23 (aa 1-24) is hydrophobic and is likely to serve as a signal peptide allowing its secretion into the blood circulation. Its carboxyl-terminal portion (aa 180-251) shares only limited amino acid homology with other members of the FGF family of proteins.

Citations

Title Year Applications Sample Species Sample Sample Details

Evaluation of a Method for Fibroblast Growth factor-23: A Novel Biomarker of Adverse Outcomes in Patients With Renal Disease.

2010

ELISA

Human

Plasma

Evaluation of a Method for Fibroblast Growth factor-23: A Novel Biomarker of Adverse Outcomes in Patients With Renal Disease.

2010

ELISA

Human

Serum

Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes.

2018

ELISA

Human

Plasma

Diabetes

Plasma Fibroblast Growth Factor 23 Is Elevated in Pediatric Primary Hypertension.

2019

ELISA

Human

Plasma

Hypertension (Children)

Iron Deficiency, Elevated Erythropoietin, Fibroblast Growth Factor 23, and Mortality in the General Population of the Netherlands: A Cohort Study.

2019

ELISA

Human

Plasma

Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.

2020

ELISA

Human

Plasma

Chronic Kidney Disease

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

2005

ELISA

Human

Serum

Determination of fibroblast growth factor 23

2009

ELISA

Human

Plasma

Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis

2009

ELISA

Human

HEK293 cells

Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis

2009

ELISA

Human

Plasma

Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active

2010

ELISA

Human

Plasma

The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease

2010

ELISA

Human

Plasma

Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature

2011

ELISA

Human

Serum

Early skeletal and biochemical alterations in pediatric chronic kidney disease

2012

ELISA

Human

Plasma

Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function

2012

ELISA

Human

Serum

Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients

2012

ELISA

Human

Serum

Chronic Kidney Disease

Intact fibroblast growth factor 23 and fragments in plasma from Gambian children

2013

ELISA

Human

Plasma

Biological variability of plasma intact and C-terminal FGF23 measurements

2012

ELISA

Human

Plasma

Novel SLC34A3 mutation causing hereditary hypophosphataemic rickets with hypercalciuria in a Gambian family

2013

ELISA

Human

Plasma

Associations among total and food additive phosphorus intake and carotid intima-media thickness--a cross-sectional study in a middle-aged population in Southern Finland

2013

ELISA

Human

Plasma

A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients

2013

ELISA

Human

Serum

Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children

2013

ELISA

Human

Plasma

The use of fibroblast growth factor 23 testing in patients with kidney disease.

2014

ELISA

Human

Plasma

Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease

2018

ELISA

Human

Plasma

Acute Coronary Syndrome

Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin

2014

ELISA

Human

Plasma

Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients

2015

ELISA

Human

Plasma

Aortic Artery and Cardiac Valve Calcification are Associated with Mortality in Chinese Hemodialysis Patients: A 3.5 Years Follow-up

2015

ELISA

Human

Plasma

MHD

Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease

2016

ELISA

Human

Plasma

Acute Coronary Syndrome

C-Terminal to Intact Fibroblast Growth Factor 23 Ratio in Relation to Estimated Glomerular Filtration Rate in Elderly Population

2016

ELISA

Human

Plasma

Dietary phosphate supplement does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia

2016

ELISA

Human

Plasma

Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy

2016

ELISA

Human

Plasma

Fibroblast Growth Factor 23-Induced Hypophosphatemia in Acute Leukemia.

2018

ELISA

Human

Plasma

Aptamer-Based Proteomics Identifies Mortality-Associated Serum Biomarkers in Dialysis-Dependent AKI Patients

2018

ELISA

Human

Serum

The Heart and Kidney: Abnormal Phosphate Homeostasis Is Associated With Atherosclerosis.

2018

ELISA

Human

Plasma

Tumor-induced osteomalacia: experience from three tertiary care centres In India

2019

ELISA

Human

Serum

Hypoparathyroidism